Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50.

ESMO Open · 2025 · PMC12088754 · PMID 40305908

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, females showed a trend towards reduced risk of death overall, although not statistically significant (HR 0.65, 95% CI 0.42-1.01, P = 0.057).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.